ID   KPCG_HUMAN              Reviewed;         697 AA.
AC   P05129; B7Z8Q0;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 3.
DT   12-OCT-2022, entry version 233.
DE   RecName: Full=Protein kinase C gamma type;
DE            Short=PKC-gamma;
DE            EC=2.7.11.13;
GN   Name=PRKCG; Synonyms=PKCG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Cui W.C., Yu L., Chu Y.Y., Wang J., Zheng L.H., Zhou G.J., Zhao S.Y.;
RL   Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Kidney;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-317 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=3755548; DOI=10.1126/science.3755548;
RA   Coussens L., Parker P.J., Rhee L., Yang-Feng T.L., Chen E.,
RA   Waterfield M.D., Francke U., Ullrich A.;
RT   "Multiple, distinct forms of bovine and human protein kinase C suggest
RT   diversity in cellular signaling pathways.";
RL   Science 233:859-866(1986).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 162-697 (ISOFORM 1).
RC   TISSUE=Hippocampus;
RX   PubMed=8375396; DOI=10.1111/j.1432-1033.1993.tb18179.x;
RA   Kochs G., Hummel R., Meyer D., Hug H., Marme D., Sarre T.F.;
RT   "Activation and substrate specificity of the human protein kinase C alpha
RT   and zeta isoenzymes.";
RL   Eur. J. Biochem. 216:597-606(1993).
RN   [7]
RP   INTERACTION WITH CDCP1.
RX   PubMed=15851033; DOI=10.1016/j.cell.2005.02.019;
RA   Benes C.H., Wu N., Elia A.E.H., Dharia T., Cantley L.C., Soltoff S.P.;
RT   "The C2 domain of PKCdelta is a phosphotyrosine binding domain.";
RL   Cell 121:271-280(2005).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH TP53INP1 AND P53/TP53.
RX   PubMed=16377624; DOI=10.1074/jbc.m512074200;
RA   Yoshida K., Liu H., Miki Y.;
RT   "Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor
RT   suppressor in the apoptotic response to DNA damage.";
RL   J. Biol. Chem. 281:5734-5740(2006).
RN   [9]
RP   REVIEW ON FUNCTION.
RX   PubMed=12417016; DOI=10.1093/oxfordjournals.jbchem.a003274;
RA   Saito N., Shirai Y.;
RT   "Protein kinase C gamma (PKC gamma): function of neuron specific isotype.";
RL   J. Biochem. 132:683-687(2002).
RN   [10]
RP   REVIEW ON FUNCTION.
RX   PubMed=17629453; DOI=10.1016/j.cellsig.2007.05.014;
RA   Barnett M.E., Madgwick D.K., Takemoto D.J.;
RT   "Protein kinase C as a stress sensor.";
RL   Cell. Signal. 19:1820-1829(2007).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   UBIQUITINATION.
RX   PubMed=20596523; DOI=10.1371/journal.pone.0011332;
RA   Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B.,
RA   Spruck C.;
RT   "Development and validation of a method for profiling post-translational
RT   modification activities using protein microarrays.";
RL   PLoS ONE 5:E11332-E11332(2010).
RN   [13]
RP   STRUCTURE BY NMR OF 36-105.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the phorbol esters/diacylglycerol binding domain of
RT   protein kinase C gamma.";
RL   Submitted (DEC-2007) to the PDB data bank.
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 154-295 IN COMPLEX WITH CALCIUM
RP   IONS, AND COFACTOR.
RA   Pike A.C.W., Amos A., Johansson C., Sobott F., Savitsky P., Berridge G.,
RA   Fedorov O., Umeano C., Gorrec F., Bunkoczi G., Debreczeni J., Von Delft F.,
RA   Arrowsmith C.H., Edwards A., Weigelt J., Sundstrom M., Knapp S.;
RT   "Crystal structure of C2 domain of protein kinase C gamma.";
RL   Submitted (APR-2007) to the PDB data bank.
RN   [15]
RP   VARIANTS CYS-141; GLN-415; ASP-523 AND SER-659.
RX   PubMed=9545390; DOI=10.1086/301819;
RA   Al-Maghtheh M., Vithana E.N., Inglehearn C.F., Moore T., Bird A.C.,
RA   Bhattacharya S.S.;
RT   "Segregation of a PRKCG mutation in two RP11 families.";
RL   Am. J. Hum. Genet. 62:1248-1252(1998).
RN   [16]
RP   SHOWS THAT THE VARIANTS ARE NOT A CAUSE OF RP11.
RX   PubMed=10441600; DOI=10.1086/302554;
RA   Dryja T.P., McEvoy J., McGee T.L., Berson E.L.;
RT   "No mutations in the coding region of the PRKCG gene in three families with
RT   retinitis pigmentosa linked to the RP11 locus on chromosome 19q.";
RL   Am. J. Hum. Genet. 65:926-928(1999).
RN   [17]
RP   TISSUE SPECIFICITY, AND VARIANTS SCA14 TYR-101; PRO-119 AND ASP-128.
RX   PubMed=12644968; DOI=10.1086/373883;
RA   Chen D.-H., Brkanac Z., Verlinde C.L.M.J., Tan X.-J., Bylenok L.,
RA   Nochlin D., Matsushita M., Lipe H., Wolff J., Fernandez M., Cimino P.J.,
RA   Bird T.D., Raskind W.H.;
RT   "Missense mutations in the regulatory domain of PKC gamma: a new mechanism
RT   for dominant nonepisodic cerebellar ataxia.";
RL   Am. J. Hum. Genet. 72:839-849(2003).
RN   [18]
RP   VARIANTS SCA14 VAL-63 AND ARG-63, AND SUBCELLULAR LOCATION.
RX   PubMed=29053796; DOI=10.1093/brain/awx251;
RA   Nibbeling E.A.R., Duarri A., Verschuuren-Bemelmans C.C., Fokkens M.R.,
RA   Karjalainen J.M., Smeets C.J.L.M., de Boer-Bergsma J.J., van der Vries G.,
RA   Dooijes D., Bampi G.B., van Diemen C., Brunt E., Ippel E., Kremer B.,
RA   Vlak M., Adir N., Wijmenga C., van de Warrenburg B.P.C., Franke L.,
RA   Sinke R.J., Verbeek D.S.;
RT   "Exome sequencing and network analysis identifies shared mechanisms
RT   underlying spinocerebellar ataxia.";
RL   Brain 140:2860-2878(2017).
CC   -!- FUNCTION: Calcium-activated, phospholipid- and diacylglycerol (DAG)-
CC       dependent serine/threonine-protein kinase that plays diverse roles in
CC       neuronal cells and eye tissues, such as regulation of the neuronal
CC       receptors GRIA4/GLUR4 and GRIN1/NMDAR1, modulation of receptors and
CC       neuronal functions related to sensitivity to opiates, pain and alcohol,
CC       mediation of synaptic function and cell survival after ischemia, and
CC       inhibition of gap junction activity after oxidative stress. Binds and
CC       phosphorylates GRIA4/GLUR4 glutamate receptor and regulates its
CC       function by increasing plasma membrane-associated GRIA4 expression. In
CC       primary cerebellar neurons treated with the agonist 3,5-
CC       dihyidroxyphenylglycine, functions downstream of the metabotropic
CC       glutamate receptor GRM5/MGLUR5 and phosphorylates GRIN1/NMDAR1 receptor
CC       which plays a key role in synaptic plasticity, synaptogenesis,
CC       excitotoxicity, memory acquisition and learning. May be involved in the
CC       regulation of hippocampal long-term potentiation (LTP), but may be not
CC       necessary for the process of synaptic plasticity. May be involved in
CC       desensitization of mu-type opioid receptor-mediated G-protein
CC       activation in the spinal cord, and may be critical for the development
CC       and/or maintenance of morphine-induced reinforcing effects in the
CC       limbic forebrain. May modulate the functionality of mu-type-opioid
CC       receptors by participating in a signaling pathway which leads to the
CC       phosphorylation and degradation of opioid receptors. May also
CC       contributes to chronic morphine-induced changes in nociceptive
CC       processing. Plays a role in neuropathic pain mechanisms and contributes
CC       to the maintenance of the allodynia pain produced by peripheral
CC       inflammation. Plays an important role in initial sensitivity and
CC       tolerance to ethanol, by mediating the behavioral effects of ethanol as
CC       well as the effects of this drug on the GABA(A) receptors. During and
CC       after cerebral ischemia modulate neurotransmission and cell survival in
CC       synaptic membranes, and is involved in insulin-induced inhibition of
CC       necrosis, an important mechanism for minimizing ischemic injury.
CC       Required for the elimination of multiple climbing fibers during
CC       innervation of Purkinje cells in developing cerebellum. Is activated in
CC       lens epithelial cells upon hydrogen peroxide treatment, and
CC       phosphorylates connexin-43 (GJA1/CX43), resulting in disassembly of
CC       GJA1 gap junction plaques and inhibition of gap junction activity which
CC       could provide a protective effect against oxidative stress (By
CC       similarity). Phosphorylates p53/TP53 and promotes p53/TP53-dependent
CC       apoptosis in response to DNA damage. Involved in the phase resetting of
CC       the cerebral cortex circadian clock during temporally restricted
CC       feeding. Stabilizes the core clock component ARNTL/BMAL1 by interfering
CC       with its ubiquitination, thus suppressing its degradation, resulting in
CC       phase resetting of the cerebral cortex clock (By similarity).
CC       {ECO:0000250|UniProtKB:P63318, ECO:0000250|UniProtKB:P63319,
CC       ECO:0000269|PubMed:16377624}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.13;
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU00041, ECO:0000269|Ref.14};
CC       Note=Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2
CC       domain. {ECO:0000269|Ref.14};
CC   -!- ACTIVITY REGULATION: Classical (or conventional) PKCs (PRKCA, PRKCB and
CC       PRKCG) are activated by calcium and diacylglycerol (DAG) in the
CC       presence of phosphatidylserine. Three specific sites; Thr-514
CC       (activation loop of the kinase domain), Thr-655 (turn motif) and Thr-
CC       674 (hydrophobic region), need to be phosphorylated for its full
CC       activation.
CC   -!- SUBUNIT: Interacts with GRIA4 (By similarity). Interacts with CDCP1.
CC       Interacts with TP53INP1 and p53/TP53. Interacts with ARNTL/BMAL1 (By
CC       similarity). {ECO:0000250|UniProtKB:P63318,
CC       ECO:0000269|PubMed:15851033, ECO:0000269|PubMed:16377624}.
CC   -!- INTERACTION:
CC       P05129; Q96KS9: FAM167A; NbExp=3; IntAct=EBI-949799, EBI-10290462;
CC       P05129; P08238: HSP90AB1; NbExp=2; IntAct=EBI-949799, EBI-352572;
CC       P05129; P08727: KRT19; NbExp=3; IntAct=EBI-949799, EBI-742756;
CC       P05129; O75925: PIAS1; NbExp=3; IntAct=EBI-949799, EBI-629434;
CC       P05129; Q8N6K7-2: SAMD3; NbExp=3; IntAct=EBI-949799, EBI-11528848;
CC       P05129; Q8TDR4: TCP10L; NbExp=3; IntAct=EBI-949799, EBI-3923210;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P63318}.
CC       Cytoplasm, perinuclear region {ECO:0000250}. Cell membrane
CC       {ECO:0000269|PubMed:29053796}; Peripheral membrane protein
CC       {ECO:0000250}. Synapse, synaptosome {ECO:0000250|UniProtKB:P63318}.
CC       Cell projection, dendrite {ECO:0000250|UniProtKB:P63319}.
CC       Note=Translocates to synaptic membranes on stimulation.
CC       {ECO:0000250|UniProtKB:P63318}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P05129-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P05129-2; Sequence=VSP_056467, VSP_056468, VSP_056469;
CC   -!- TISSUE SPECIFICITY: Expressed in Purkinje cells of the cerebellar
CC       cortex. {ECO:0000269|PubMed:12644968}.
CC   -!- PTM: Autophosphorylation on Thr-674 appears to regulate motor functions
CC       of junctophilins, JPH3 and JPH4. {ECO:0000250|UniProtKB:P63318}.
CC   -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:20596523}.
CC   -!- DISEASE: Spinocerebellar ataxia 14 (SCA14) [MIM:605361]:
CC       Spinocerebellar ataxia is a clinically and genetically heterogeneous
CC       group of cerebellar disorders. Patients show progressive incoordination
CC       of gait and often poor coordination of hands, speech and eye movements,
CC       due to degeneration of the cerebellum with variable involvement of the
CC       brainstem and spinal cord. SCA14 is an autosomal dominant cerebellar
CC       ataxia (ADCA). {ECO:0000269|PubMed:12644968,
CC       ECO:0000269|PubMed:29053796}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Mutations of the PRKCG gene; Note=Retina
CC       International's Scientific Newsletter;
CC       URL="https://www.retina-international.org/files/sci-news/prkcgmut.htm";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF345987; AAK13533.1; -; mRNA.
DR   EMBL; AK303741; BAH14036.1; -; mRNA.
DR   EMBL; AC008440; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC047876; AAH47876.1; -; mRNA.
DR   EMBL; M13977; AAA60102.1; -; mRNA.
DR   EMBL; Z15114; CAA78820.1; -; mRNA.
DR   CCDS; CCDS12867.1; -. [P05129-1]
DR   PIR; D24664; D24664.
DR   RefSeq; NP_001303258.1; NM_001316329.1.
DR   RefSeq; NP_002730.1; NM_002739.4. [P05129-1]
DR   PDB; 2E73; NMR; -; A=36-105.
DR   PDB; 2UZP; X-ray; 2.00 A; A/B/C=154-295.
DR   PDBsum; 2E73; -.
DR   PDBsum; 2UZP; -.
DR   AlphaFoldDB; P05129; -.
DR   SMR; P05129; -.
DR   BioGRID; 111568; 68.
DR   DIP; DIP-39795N; -.
DR   IntAct; P05129; 42.
DR   MINT; P05129; -.
DR   STRING; 9606.ENSP00000263431; -.
DR   BindingDB; P05129; -.
DR   ChEMBL; CHEMBL2938; -.
DR   DrugBank; DB09096; Benzoyl peroxide.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugCentral; P05129; -.
DR   GuidetoPHARMACOLOGY; 1484; -.
DR   iPTMnet; P05129; -.
DR   PhosphoSitePlus; P05129; -.
DR   SwissPalm; P05129; -.
DR   BioMuta; PRKCG; -.
DR   DMDM; 462455; -.
DR   EPD; P05129; -.
DR   jPOST; P05129; -.
DR   MassIVE; P05129; -.
DR   MaxQB; P05129; -.
DR   PaxDb; P05129; -.
DR   PeptideAtlas; P05129; -.
DR   PRIDE; P05129; -.
DR   ProteomicsDB; 51803; -. [P05129-1]
DR   ProteomicsDB; 6967; -.
DR   Antibodypedia; 32756; 671 antibodies from 38 providers.
DR   DNASU; 5582; -.
DR   Ensembl; ENST00000263431.4; ENSP00000263431.3; ENSG00000126583.12. [P05129-1]
DR   GeneID; 5582; -.
DR   KEGG; hsa:5582; -.
DR   MANE-Select; ENST00000263431.4; ENSP00000263431.3; NM_002739.5; NP_002730.1.
DR   UCSC; uc002qcq.2; human. [P05129-1]
DR   CTD; 5582; -.
DR   DisGeNET; 5582; -.
DR   GeneCards; PRKCG; -.
DR   GeneReviews; PRKCG; -.
DR   HGNC; HGNC:9402; PRKCG.
DR   HPA; ENSG00000126583; Tissue enriched (brain).
DR   MalaCards; PRKCG; -.
DR   MIM; 176980; gene.
DR   MIM; 605361; phenotype.
DR   neXtProt; NX_P05129; -.
DR   OpenTargets; ENSG00000126583; -.
DR   Orphanet; 98763; Spinocerebellar ataxia type 14.
DR   PharmGKB; PA33766; -.
DR   VEuPathDB; HostDB:ENSG00000126583; -.
DR   eggNOG; KOG0696; Eukaryota.
DR   GeneTree; ENSGT00940000161219; -.
DR   HOGENOM; CLU_000288_54_2_1; -.
DR   InParanoid; P05129; -.
DR   OMA; DLKSQHT; -.
DR   OrthoDB; 614710at2759; -.
DR   PhylomeDB; P05129; -.
DR   TreeFam; TF351133; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   PathwayCommons; P05129; -.
DR   Reactome; R-HSA-111933; Calmodulin induced events.
DR   Reactome; R-HSA-114516; Disinhibition of SNARE formation.
DR   Reactome; R-HSA-416993; Trafficking of GluR2-containing AMPA receptors.
DR   Reactome; R-HSA-418597; G alpha (z) signalling events.
DR   Reactome; R-HSA-5099900; WNT5A-dependent internalization of FZD4.
DR   Reactome; R-HSA-76005; Response to elevated platelet cytosolic Ca2+.
DR   SignaLink; P05129; -.
DR   SIGNOR; P05129; -.
DR   BioGRID-ORCS; 5582; 14 hits in 1104 CRISPR screens.
DR   ChiTaRS; PRKCG; human.
DR   EvolutionaryTrace; P05129; -.
DR   GeneWiki; PRKCG; -.
DR   GenomeRNAi; 5582; -.
DR   Pharos; P05129; Tchem.
DR   PRO; PR:P05129; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P05129; protein.
DR   Bgee; ENSG00000126583; Expressed in right frontal lobe and 113 other tissues.
DR   ExpressionAtlas; P05129; baseline and differential.
DR   Genevisible; P05129; HS.
DR   GO; GO:0044305; C:calyx of Held; IEA:Ensembl.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0099524; C:postsynaptic cytosol; IEA:Ensembl.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0099523; C:presynaptic cytosol; IEA:Ensembl.
DR   GO; GO:0097060; C:synaptic membrane; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004698; F:calcium-dependent protein kinase C activity; IEA:UniProtKB-EC.
DR   GO; GO:0004672; F:protein kinase activity; IDA:HGNC-UCL.
DR   GO; GO:0004697; F:protein kinase C activity; TAS:ProtInc.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:MGI.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0007268; P:chemical synaptic transmission; IEA:Ensembl.
DR   GO; GO:0007635; P:chemosensory behavior; IEA:Ensembl.
DR   GO; GO:0060384; P:innervation; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0007611; P:learning or memory; IEA:Ensembl.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:1901799; P:negative regulation of proteasomal protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IDA:HGNC-UCL.
DR   GO; GO:0031397; P:negative regulation of protein ubiquitination; IDA:HGNC-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0016310; P:phosphorylation; IDA:HGNC-UCL.
DR   GO; GO:0032425; P:positive regulation of mismatch repair; IDA:HGNC-UCL.
DR   GO; GO:0099171; P:presynaptic modulation of chemical synaptic transmission; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0050764; P:regulation of phagocytosis; IEA:Ensembl.
DR   GO; GO:0032095; P:regulation of response to food; ISS:UniProtKB.
DR   GO; GO:2000300; P:regulation of synaptic vesicle exocytosis; IEA:Ensembl.
DR   GO; GO:0043278; P:response to morphine; ISS:UniProtKB.
DR   GO; GO:0048265; P:response to pain; ISS:UniProtKB.
DR   GO; GO:1990911; P:response to psychosocial stress; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   CDD; cd00029; C1; 2.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR014375; Protein_kinase_C_a/b/g.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000550; PKC_alpha; 1.
DR   PRINTS; PR00360; C2DOMAIN.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57889; SSF57889; 2.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Biological rhythms;
KW   Calcium; Cell membrane; Cell projection; Cytoplasm; Disease variant;
KW   Kinase; Membrane; Metal-binding; Neurodegeneration; Nucleotide-binding;
KW   Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Spinocerebellar ataxia; Synapse;
KW   Synaptosome; Transferase; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..697
FT                   /note="Protein kinase C gamma type"
FT                   /id="PRO_0000055689"
FT   DOMAIN          157..275
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   DOMAIN          351..614
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          615..685
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   ZN_FING         35..85
FT                   /note="Phorbol-ester/DAG-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   ZN_FING         100..150
FT                   /note="Phorbol-ester/DAG-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   ACT_SITE        480
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         186
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         187
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         187
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         193
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         246
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         246
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         247
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         248
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         248
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         248
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         251
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         252
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         254
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         254
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         357..365
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         380
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         250
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         320
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P63318"
FT   MOD_RES         322
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P63318"
FT   MOD_RES         326
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P63318"
FT   MOD_RES         328
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P63318"
FT   MOD_RES         330
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P63318"
FT   MOD_RES         332
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P63318"
FT   MOD_RES         373
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P63318"
FT   MOD_RES         514
FT                   /note="Phosphothreonine; by PDPK1"
FT                   /evidence="ECO:0000250|UniProtKB:P63318"
FT   MOD_RES         648
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         655
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P63318"
FT   MOD_RES         674
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P63318"
FT   MOD_RES         675
FT                   /note="Phosphotyrosine; by SYK"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         687
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P63319"
FT   VAR_SEQ         1..20
FT                   /note="MAGLGPGVGDSEGGPRPLFC -> MPRICDLRVSRRWEGPPDGR (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056467"
FT   VAR_SEQ         21..133
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056468"
FT   VAR_SEQ         553..588
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056469"
FT   VARIANT         63
FT                   /note="G -> R (in SCA14)"
FT                   /evidence="ECO:0000269|PubMed:29053796"
FT                   /id="VAR_080740"
FT   VARIANT         63
FT                   /note="G -> V (in SCA14; dbSNP:rs386134159)"
FT                   /evidence="ECO:0000269|PubMed:29053796"
FT                   /id="VAR_080741"
FT   VARIANT         101
FT                   /note="H -> Y (in SCA14; dbSNP:rs121918511)"
FT                   /evidence="ECO:0000269|PubMed:12644968"
FT                   /id="VAR_017060"
FT   VARIANT         119
FT                   /note="S -> P (in SCA14; dbSNP:rs121918512)"
FT                   /evidence="ECO:0000269|PubMed:12644968"
FT                   /id="VAR_017061"
FT   VARIANT         128
FT                   /note="G -> D (in SCA14; dbSNP:rs121918513)"
FT                   /evidence="ECO:0000269|PubMed:12644968"
FT                   /id="VAR_017062"
FT   VARIANT         141
FT                   /note="R -> C"
FT                   /evidence="ECO:0000269|PubMed:9545390"
FT                   /id="VAR_008755"
FT   VARIANT         415
FT                   /note="H -> Q"
FT                   /evidence="ECO:0000269|PubMed:9545390"
FT                   /id="VAR_008756"
FT   VARIANT         523
FT                   /note="A -> D"
FT                   /evidence="ECO:0000269|PubMed:9545390"
FT                   /id="VAR_008757"
FT   VARIANT         659
FT                   /note="R -> S (in dbSNP:rs752933837)"
FT                   /evidence="ECO:0000269|PubMed:9545390"
FT                   /id="VAR_008758"
FT   CONFLICT        314..317
FT                   /note="RVRM -> VSRT (in Ref. 5; AAA60102)"
FT                   /evidence="ECO:0000305"
FT   TURN            50..52
FT                   /evidence="ECO:0007829|PDB:2E73"
FT   STRAND          57..59
FT                   /evidence="ECO:0007829|PDB:2E73"
FT   TURN            67..69
FT                   /evidence="ECO:0007829|PDB:2E73"
FT   HELIX           75..80
FT                   /evidence="ECO:0007829|PDB:2E73"
FT   TURN            86..89
FT                   /evidence="ECO:0007829|PDB:2E73"
FT   STRAND          160..169
FT                   /evidence="ECO:0007829|PDB:2UZP"
FT   STRAND          172..182
FT                   /evidence="ECO:0007829|PDB:2UZP"
FT   STRAND          194..201
FT                   /evidence="ECO:0007829|PDB:2UZP"
FT   STRAND          222..230
FT                   /evidence="ECO:0007829|PDB:2UZP"
FT   HELIX           233..237
FT                   /evidence="ECO:0007829|PDB:2UZP"
FT   STRAND          239..246
FT                   /evidence="ECO:0007829|PDB:2UZP"
FT   STRAND          249..251
FT                   /evidence="ECO:0007829|PDB:2UZP"
FT   STRAND          254..262
FT                   /evidence="ECO:0007829|PDB:2UZP"
FT   HELIX           263..268
FT                   /evidence="ECO:0007829|PDB:2UZP"
FT   STRAND          271..276
FT                   /evidence="ECO:0007829|PDB:2UZP"
FT   HELIX           280..283
FT                   /evidence="ECO:0007829|PDB:2UZP"
SQ   SEQUENCE   697 AA;  78448 MW;  3F911B5BEF713C41 CRC64;
     MAGLGPGVGD SEGGPRPLFC RKGALRQKVV HEVKSHKFTA RFFKQPTFCS HCTDFIWGIG
     KQGLQCQVCS FVVHRRCHEF VTFECPGAGK GPQTDDPRNK HKFRLHSYSS PTFCDHCGSL
     LYGLVHQGMK CSCCEMNVHR RCVRSVPSLC GVDHTERRGR LQLEIRAPTA DEIHVTVGEA
     RNLIPMDPNG LSDPYVKLKL IPDPRNLTKQ KTRTVKATLN PVWNETFVFN LKPGDVERRL
     SVEVWDWDRT SRNDFMGAMS FGVSELLKAP VDGWYKLLNQ EEGEYYNVPV ADADNCSLLQ
     KFEACNYPLE LYERVRMGPS SSPIPSPSPS PTDPKRCFFG ASPGRLHISD FSFLMVLGKG
     SFGKVMLAER RGSDELYAIK ILKKDVIVQD DDVDCTLVEK RVLALGGRGP GGRPHFLTQL
     HSTFQTPDRL YFVMEYVTGG DLMYHIQQLG KFKEPHAAFY AAEIAIGLFF LHNQGIIYRD
     LKLDNVMLDA EGHIKITDFG MCKENVFPGT TTRTFCGTPD YIAPEIIAYQ PYGKSVDWWS
     FGVLLYEMLA GQPPFDGEDE EELFQAIMEQ TVTYPKSLSR EAVAICKGFL TKHPGKRLGS
     GPDGEPTIRA HGFFRWIDWE RLERLEIPPP FRPRPCGRSG ENFDKFFTRA APALTPPDRL
     VLASIDQADF QGFTYVNPDF VHPDARSPTS PVPVPVM
//
